Depressive Symptoms
Conditions
Keywords
Depression, Mindfulness, MBCT
Brief summary
The purpose of this study is to determine whether both group and individual mindfulness-based cognitive therapy (MBCT) are effective in reducing depressive symptoms in patients with a chronic somatic disease.
Detailed description
Depression is a common co-morbidity in patients with a chronic somatic disease which has a negative impact on patients' physical and mental health. In recent years, Mindfulness-Based Cognitive Therapy (MBCT) has gained interest and popularity as a treatment not only for preventing recurrence of depression, but also to treat current symptoms. Usually, the training is delivered in group format, thus little is known about the feasibility and effectiveness of MBCT as an individual training. This pilot study aims to compare the effectiveness and feasibility of group and individual MBCT in reducing depressive symptoms in patients with a chronic somatic disease.
Interventions
BEHAVIORALGroup-Mindfulness-Based Cognitive Therapy
The intervention consists of 8 weekly sessions of MBCT. Each session will be administered in a group and will last 2 1/2 hours.
BEHAVIORALIndividual-Mindfulness-Based Cognitive Therapy
The intervention consists of 8 weekly sessions of MBCT. Each session will be administered individually and will last 45 to 60 minutes.
Sponsors
University of Groningen
University Medical Center Groningen
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Chronic somatic disease * Age ≥ 18 and ≤ 70 * Depressive symptoms as assessed by BDI-II score ≥ 14 (cut-off score indicating the presence of at least mild symptoms of depression)
Exclusion criteria
* Not being able to read and write Dutch * Severe (psychiatric) co-morbidity * Acute suicidal ideations or behavior * Receiving an alternative psychological treatment during or less than two months prior to starting the participation in the study Using an antidepressant drug during participation in the present study is allowed, on condition that a patient has been on stable medication regimen for at least two months prior to inclusion in the study, and that no new treatment with an antidepressant is initiated during the course of the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in severity of depressive symptoms | Pre-treatment to post-treatment (primary measurement point; approximately 3 months after pre-treatment) and 3-months follow-up | Severity of depressive symptoms are assessed with the Beck Depression Inventory-II |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in well-being | Pre-treatment to post-treatment (primary measurement point; approximately 3 months after pre-treatment) and 3-months follow-up | Well-being is measured by the Well-being Index (WHO-5) |
| Change in generalized anxiety | Pre-treatment to post-treatment (primary measurement point; approximately 3 months after pre-treatment) and 3-months follow-up | Generalized anxiety is measured by the Generalised Anxiety Disorder Assessment (GAD 7) |
Other
| Measure | Time frame | Description |
|---|---|---|
| Change in mindfulness | Pre-treatment to post-treatment (primary measurement point; approximately 3 months after pre-treatment) and 3-months follow-up | Mindfulness is assessed with the Five Facet Mindfulness Questionnaire (FFMQ) |
| Change in self-compassion | Pre-treatment to post-treatment (primary measurement point; approximately 3 months after pre-treatment) and 3-months follow-up | Self-compassion is assessed with the 12 item Self-Compassion Scales |
Outcome results
None listed